Document is current
Any future updates will be listed below
-
Authors
Starble, Rebecca M. https://orcid.org/0000-0002-7724-0761
Sun, Eric G. https://orcid.org/0000-0002-9109-1969
Gbyli, Rana
Radda, Jonathan https://orcid.org/0000-0002-2242-9604
Lu, Jiuwei https://orcid.org/0000-0002-6478-4081
Jensen, Tyler B. https://orcid.org/0000-0003-0220-4026
Sun, Ning https://orcid.org/0000-0002-4123-5362
Khudaverdyan, Nelli
Zhao, Ting
Hu, Bomiao https://orcid.org/0009-0001-4697-0577
Melnick, Mary Ann
Zhao, Shuai https://orcid.org/0000-0003-4240-2430
Roper, Nitin
Wang, Gang Greg https://orcid.org/0000-0002-7210-9940
Tackett, Alan J.
Wang, Yinsheng
Song, Jikui
Politi, Katerina
Wang, Siyuan https://orcid.org/0000-0001-6550-4064
Xiao, Andrew Z. https://orcid.org/0000-0001-6578-8669
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 26 August 2025
First Online: 23 October 2025
Competing interests
: K.P. has grants from AstraZeneca, Roche/Genentech, Boehringer Ingelheim and D2G Oncology; personal fees from AstraZeneca and Revelio Therapeutics, Inc; and a patent related to EGFR T790M mutation testing with royalties paid “from MSKCC/MolecularMD”. K.P. is a co-founder of and consultant for Revelio Therapeutics, Inc. All other authors declare no competing interests.
